Key Insights

Highlights

Treatment Research

3 treatments under study, led by Lcar F33s Cells Intravenous Infusion

Research Leaders

8 sponsors active, led by Zhujiang Hospital

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 1 (1)

Trial Status

Recruiting2
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07100067Not ApplicableRecruitingPrimary

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

NCT07139509Phase 1RecruitingPrimary

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

NCT03473496Not ApplicableTerminatedPrimary

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma

Showing all 3 trials

Research Network

Common Treatments

  • Lcar F33s Cells Intravenous Infusion1
  • Allogeneic Cord Bloodderived Dualtargeting Cd19bcma Cart Cells1
  • Cart Therapy In Relapsedrefractory Multiple Myeloma1

Active Sponsors

  • Zhujiang Hospital1
  • Xi'an No.3 Hospital1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Ucello Therapeutics Co., Limited1
  • Institute of Hematology & Blood Diseases Hospital, China1

Top Investigators

Activity Timeline